Routine testing for clopidogrel responsiveness may avert DES (drug-eluting stent) thrombosis
This article was originally published in Clinica
In what might help avoid the risk of developing thrombosis inside a drug-eluting stent (DES), doctors should test patients for their responsiveness to the antiplatelet agent clopidogrel before deciding whether the device should be implanted, an Italian trial has suggested.
You may also be interested in...
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.